In Brief: Biogen's Avonex
Executive Summary
Biogen's Avonex: Berlex motion to block approval of the beta interferon product for multiple sclerosis is denied by D.C. federal court Judge James Robertson April 30. Berlex still could file for an injunction upon approval of Avonex. The marketer of Betaseron filed a lawsuit on April 26 claiming that Avonex violates Betaseron orphan exclusivity and that Biogen has not shown comparability between the beta interferon product it will manufacture and market and the product used in clinical trials manufactured by Dr. Rentschler Arzneimittel, GmbH in Germany ("The Pink Sheet" April 29, p. 15)...